IP Library Granted Patent US 9,265,725
Granted Patent B2
US 9,265,725 · App. 11/825,406 · Granted Feb 23, 2016

Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,265,725
App. No.
11/825,406
Granted
Feb 23, 2016
Kind
B2
Abstract

The present invention teaches a foamable pharmaceutical carrier comprising a benefit agent, selected from the group consisting of a dicarboxylic acid and a dicarboxylic acid ester; a stabilizer selected from the group consisting of at least one surface-active agent; at least one polymeric agent and mixtures thereof; a solvent selected from the group consisting of water, a hydrophilic solvent, a hydrophobic solvent, a potent solvent, a polar solvent, a silicone, an emollient, and mixtures thereof, wherein the benefit agent, stabilizer and solvent are selected to provide a composition that is substantially resistant to aging and to phase separation and or can substantially stabilize other active ingredients. The invention further relates to a foamable composition further containing a liquefied hydrocarbon gas propellant.

Claims (37)

1. A foamable composition comprising a formable carrier and a propellant, the foamable carrier comprising:

a) about 15% by weight of an azelaic acid;

b) about 11% by weight of medium-chain triglycerides;

c) about 11% by weight of propylene glycol;

d) about 5% by weight of dimethyl isosorbide;

e) about 3% by weight of PEG-40 stearate;

f) about 1% by weight of a cetostearyl alcohol;

g) about 1% by weight of polysorbate 80;

h) about 0.5% by weight of a monoglyceride, a diglyceride, or a combination;

i) about 0.3% by weight of a xanthan gum;

j) about 0.1% by weight of methylcellulose;

k) about 0.1% by weight of a benzoic acid;

l) water;

m) sodium hydroxide; and

wherein the pH of said foamable carrier is about 4.5-5.3; and

wherein the propellant is at a concentration of about 3% to about 25% by weight of the total composition.

2. The foamable composition of claim 1 , wherein the medium-chain triglycerides are caprylic/capric triglycerides.

3. The foamable composition of claim 1 , wherein the monoglyceride is glyceryl stearate.

4. The foamable composition of claim 1 , wherein the medium-chain triglycerides are caprylic/capric triglycerides and the monoglyceride is glyceryl stearate.

5. A foamable carrier comprising:

a) about 15% by weight of an azelaic acid;

b) about 11% by weight of medium-chain triglycerides;

c) about 11% by weight of propylene glycol;

d) about 5% by weight of dimethyl isosorbide;

c) about 3% by weight of PEG-40 stearate;

f) about 1% by weight of a cetostearyl alcohol;

g) about 1% by weight of polysorbate 80;

h) about 0.5% by weight of a monoglyceride, a diglyceride, or a combination thereof;

i) about 0.3% by weight of a xanthan gum;

j) about 0.1% by weight of methylcellulose;

k) about 0.1% by weight of a benzoic acid;

l) water;

m) sodium hydroxide; and

wherein the pH of said foamable carrier is about 4.5-5.3.

6. The foamable carrier of claim 5 , wherein the medium-chain triglycerides are caprylic/capric triglycerides.

7. The foamable carrier of claim 5 , wherein the monoglyceride is glyceryl stearate.

8. The foamable carrier of claim 5 , wherein the medium-chain triglycerides are caprylic/capric triglycerides and the monoglyceride is glyceryl stearate.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2021
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: VYNE PHARMACEUTICALS LTD. (F/K/A FOAMIX PHARMACEUTICALS LTD.)
Reel/Frame 057544/0138 →
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2021
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.)
Reel/Frame 057544/0708 →
PATENT SECURITY AGREEMENT Recorded Feb 17, 2021
From: VYNE THERAPEUTICS INC.
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 055326/0009 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2021
From: VYNE PHARMACEUTICALS LTD.
To: VYNE THERAPEUTICS INC.
Reel/Frame 055215/0298 →
CHANGE OF NAME Recorded Nov 4, 2020
From: FOAMIX PHARMACEUTICALS LTD.
To: VYNE PHARMACEUTICALS LTD.
Reel/Frame 054306/0387 →
PATENT SECURITY AGREEMENT Recorded Jul 30, 2019
From: FOAMIX PHARMACEUTICALS LTD
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 049912/0045 →
CHANGE OF NAME Recorded Jul 30, 2014
From: FOAMIX LTD.
To: FOAMIX PHARMACEUTICALS LTD.
Reel/Frame 033445/0249 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2007
From: TAMARKIN, DOV; FRIEDMAN, DORON; BERMAN, TAL; ZIV, ENBAL; SCHUZ, DAVID
To: FOAMIX, LTD.
Reel/Frame 020094/0430 →